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Summary 
Macrophages and granulocytes seem to play a key role in the pathogenesis of bacterial meningitis. 
Transforming growth factor B (TGF-~) leads to macrophage deactivation, as well as to inhibition 
of cytokine production and of endothelial granulocyte adhesion. We have investigated the influence 
of TGF-~ on regional cerebral blood flow (rCBF), intracranial  pressure (ICP), and brain edema 
formation during the early phase of experimental meningitis.  Rats  which were inoculated 
intracisternally with live pneumococci or with pneumococcal cell wall hydrolyzed by the M1 
muramidase (PCW-M) developed an increase of rCBF and ICP within 4 h postintracisternal 
challenge.  A  single intraperitoneal injection of TGF-B2 but  not  of TGF-~2  vehicle-control 
prevented the changes of rCBF. Furthermore, TGF-~2 significantly reduced the increase of ICP 
in rats inoculated with PCW-M. Likewise, the devation of brain water content after intracisternal 
injection of pneumococci or PCW-M was blocked by pretreatment of rats with TGF-/~2. TGF-31 
exhibited similar inhibitory effects in PCW-M-injected rats.  The beneficial effects of TGF-Fl2 
on the initial phase after pneumococcal inoculation seem to be tumor necrosis factor cr- (TNF-c,) 
independent since (a) intracistemal or intraperitoneal injection of neutralizing anti-TNF-a antibodies 
did not significantly influence rCBF, ICE and brain water content in PCW-M-induced meningitis; 
and (b) TNF-oe was only occasionally detected at low levels in cerebrospinal  fluid at 4 h after 
PCW-M application. 
I 
n bacterial meningitis, the major determinants of cerebral 
lesions seem to be alterations in cerebral blood flow, brain 
edema, and devated intracranial pressure (ICP) (1). The mech- 
anisms leading to these changes involve both bacterial com- 
ponents and host factors such as cytokines, arachidonic acid 
metabolites, platelet activating factor,  complement factors, 
granulocytes, and reactive oxygen intermediates (1, 2). Elevated 
levels of TNF-c~ and IL-I~/have been detected in cerebrospinal 
fluid (CSF) of patients with bacterial meningitis, and in an- 
imal models of bacterial meningitis (3, 4). In addition, a mAb 
to TNF-o~ reduced inflammation and was also  protective 
against brain edema in a rabbit model of pneumococcal  menin- 
gitis (5). Therefore, it has been suggested that TNF-c~ may 
play a key role in the development of tissue damage in bac- 
terial meningitis. 
There is increasing evidence that TGF-B suppresses the im- 
mune response by inhibiting the expression  of MHC class 
II antigens, the growth of lymphocytes, and the formation 
of antibodies in vivo (6, 7). Furthermore, TGF-/3 may modu- 
late the inflammatory response through its interference with 
the production of cytokines, the activation of fibroblasts and 
endothelial cells, and with the deposition of extraceUuhr ma- 
trix (for review see reference 8). In the present report we dem- 
onstrate that TGF-~ suppresses disease-related cerebrovascular 
changes and brain edema formation in the early TNF-c~-in- 
dependent phase of experimental pneumococcal meningitis. 
Materials and Methods 
AnimaI Model of  Pneumococcal  Meningitis.  A well-characterized 
meningitis model, that was previously  described  in detail, was used 
(2). Male Wistar rats weighing 250-350 g were anesthetized in- 
traperitoneally with thiobutabarbiturate (100 mg/kg), tracheo- 
tomized, and artificially  ventilated (modal 683 small animal venti- 
lator; Harvard Apparatus Co. Inc., South Natick, MA). A catheter 
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Oxnard, CA) was inserted into the cisterna magna. A craniotomy 
with a diameter of 5 mm was made in the right parietal bone for 
the placement of the laser-Doppler probe (model BPM 403; TSI 
Inc., St. Paul, MN). The dura was left intact in all preparations. 
Regional cerebral blood flow (rCBF), ICP, mean  arterial  blood pres- 
sure (Statham P23 pressure transducer), and endexpiratory CO2 
(infrared CO2 analyzer, model 2200; Heyer, Bad Ems, Germany) 
were continuously  monitored on a multichannel  paper strip recorder 
(model BD 101; Kipp & Zonen, Delft, The Netherlands) and by 
a personal  computer system  after analog  digital conversion  for signal 
processing. In our previous experiments using live pneumococci, 
the increase in rCBF reached a plateau between 4- and 6-h postin- 
fection with only slight fluctuations in the mean values  (2). There- 
fore, the current investigations  were limited to the observation  period 
of 4-h postintracisternal injection. 
Brain Water  Content Determination.  At 4-h postintracistemal in- 
oculation, the rats were killed by exsanguination. The brain was 
removed, weighed in a glass dish, and dried in a stove for 16 h 
at 130~  to a stable weight. The brain water content was calcu- 
lated by (wet wt  -  dry wt)/wet wt  x  100. 
lntracisternal  Inoculum.  Highly purified pneumococcal  cell wall 
solubilized  by the M1 muramidase  (PCW-M) was used in this study. 
This preparation contains cell wall in the form of  disaccharide  Pep- 
tides and their oligomers,  with and without attached  choline  teichoic 
acid. Live pneumococci strain 6b was prepared as previously de- 
scribed (2). 
Induction of Meningitis.  When a stable baseline of rCBF and 
ICP for 30 min was achieved, 75 #1 CSF was removed through 
the intracisternal  catheter, as described  previously  (2). The rats were 
challenged intracisternally with 75  /zl  107  CFU/ml live pneu- 
mococci, or 200/~g PCW-M. Both preparations had a pH of 7.4. 
PBS was injected into the control animals. 
Effect of TGF-~2.  Recombinant human TGF-32 (10 #g) (6) 
was injected intraperitoneally  in a volume of  0.2 ml PBS containing 
0.1% BSA. TGF-fl~ or the vehicle of TGF-B2 (vehTGr-a) was in- 
jected 1 h before intracisternal  pneumococcal  challenge.  TGF-B  was 
tested at 10 #g, since this dose has been found recently to be most 
effective (6, 7). In an additional series (three rats), we tested the 
effect of 10 #g TGF-B1 on rCBF and ICP in PCW-M-injected 
rats. 
Effect of a Polyclonal TNF-cr Ah  We used a neutralizing poly- 
donal rabbit anti-mouse TNF-c~ antiserum (anti-TNF-ol; Genzyme 
Corp., Boston, MA) crossreacting with rat TNF-c~. We showed 
that  this  Ab  completely neutralized TNF-c~ activity of LPS- 
stimulated rat  macrophage supernatants with at least 10  s neu- 
tralizing U/ml. Anti-TNF were either injected intracisternally (20 
/xl) or intraperitoneally (100 /xl) together  with PCW-M (three 
animals each). 
Assay.for TNF-oe.  TNF-c~  was quantitated in a bioassay  using 
the TNF-sensitive bM cells (3), 
StatisticalAnat~sis.  rCBF and ICP were compared against time 
from the point of intracisternal injection every  30 min for 4 h. The 
different  groups of animals were compared  for rCBF, ICP, and brain 
water content  using one-way analysis of variance and Student- 
Newman-Keuls multiple comparisons. A p value of <0.05 was con- 
sidered significant. Data are given as mean  _+  SD. 
Results and Discussion 
Irrespective of whether rats were inoculated with live pneu- 
mococci or with PCW-M, and irrespective of TGF-B2 treat- 
ment PaO2, PaCO2,  pH, mean arterial  blood pressure,  and 
hematocrit levels remained within the normal ranges in all 
groups during the whole experiment (data not shown). Histo- 
logical examinations at 4 h after injection revealed slight menin- 
geal inflammatory  infiltrates located mainly in the leptomenin- 
geal space of the posterior fossa and the base of the cerebrum. 
Furthermore,  at  4  h  after infection, meningeal polymor- 
phonuclear  inflammation was  detected in  only 7/15  rats 
pretreated with vehTGF-~, and in 2/9 rats pretreated with 
TGF-~2.  Intracerebral inoculation of PBS did not lead to 
meningeal inflammation in rats pretreated with vehTGF-a or 
pretreated with TGF-32 (six rats each).  Previously,  we have 
shown  that  at  6-h  postinfection, histological evidence  of 
meningeal inflammation was uniformly detectable (2). 
rCBF  and ICP did not change in rats pretreated with 
TGF-~2 or vehT~F-a and then injected intracisternally with 
PBS (see legend to Fig.  1). In rats pretreated with vehTcr-o 
and  inoculated intracisternally with  live  pneumococci  or 
PCW-M, rCBF continuously increased during the 4-h period 
postintracisternal injection (Fig.  1). Furthermore, an eleva- 
tion of ICP was noted at 4 h after intracisternal challenge 
of PCW-M (Fig.  1) or live pneumococci (data not shown). 
TGF-B2 inhibited the increase of both rCBF and ICP. The 
suppressive  effect of TGF-B2  on rCBF was observed  at all 
time points recorded after 1 h of intracisternal infection with 
pneumococci or PCW-M (Fig.  1). TGF-B1 inhibited the in- 
crease of rCBF and ICP in PCW-M-injected rats in a similar 
fashion (e.g., at 4-h postintracisternal injection rCBF was 121.5 
_+  14.7%,  and ICP was 4.4  +  0.8 mmHg). 
Brain  water  content  was  significantly elevated  in  rats 
pretreated with vehTcF-fl and inoculated intracisternally with 
live pneumococci (79.27  _+  0.23%) or PCW-M (79.35  _+ 
0.18%), as compared to rats pretreated  with veh~r,  fl and in- 
oculated intracisternaUy  with PBS (78.87  _+ 0.19%), or rats 
pretreated with TGF-fl2 and inoculated intracisternaUy with 
PBS (78.90  _+  0.24%). TGF-fl2 pretreatment prevented the 
increase of brain water content in rats challenged intracister- 
nally with live pneumococci (78.90  _+  0.12%) of PCW-M 
(78.98  _+  0.23%)  (p <  0.05). 
Unlike TGF-fl2, anti-TNF-ol antibodies given intracister- 
nally or intraperitoneaUy did not significantly reduce the in- 
crease of rCBF in animals inoculated with PCW-M (Fig. 2). 
ICP increased  from a baseline  of 3.9  _+  0.4 mmHg to 5.8 
+_  2.2 mmHg in intracisternal anti-TNF-ot-treated rats, and 
from a baseline  of 3.4  _+  2.4 mmHg to 5.7  _+  1.8 in in- 
traperitoneal  anti-TNF-ol-treated rats (NS compared with 9.8 
-+  2.9 mmHg in PCW-M-injected, untreated rats).  Brain 
water content was elevated both in intracisternal anti-TNF- 
oe-treated  (79.40  +_  0.16%)  and intraperitoneal anti-TNF- 
oe-treated rats (79.29  _+  0.01%) (NS compared to 79.33  + 
0.18% in PCW-M-injected, untreated rats).  Effectiveness of 
anti-TNF-cz treatment is documented by the observation of 
decreased CSF cell counts at later time points after infection, 
e.g., at 6 h (1,620  _+  1,417 cells//~l, n  =  5, with treatment, 
4,725  _+ 2,636 ceUs/#l, n =  4, without treatment, p < 0.05). 
These data confirm recent studies in rabbits infected with 
pneumococci in which, 6 h after infection, anti-TNF-o~ anti- 
bodies reduced pleocytosis (5). 
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Effect of TGF-fl2 on rCBF in rats challenged with live pneu-  Figure  1. 
mococci or pneumococcal cen wall components (PCW-M). rCBF was ex- 
pressed as percentage of the baseline values (= 100%). Within 4 h postin- 
tracisternal (i,) injection of PBS rCBF did not change in rats pretreated 
intraperitoneally (i.p) with TGF-B2 (n  =  7) or vehTor-a (n  =  7) (rCBF 
103.8  -+  16.3%  and  110.0  -+  10.8%,  respectively).  However,  in  rats 
pretreated with vehTor-a and inoculated intracisternally with live pneu- 
mococci, rCBF increased to 161.0  _+  14.3% within 4-h postintracisternal 
injection (n  =  8). The increase in rCBF was inhibited by TGF-B2 pretreat- 
ment (110.2  _+  16.0% at 4-h postintracisternal injection; n  =  7). At 4-h 
postintracisternal  inoculation,  rats pretreated  with veliTGr-a and inocu- 
lated intracisternally with PCW-M (n  =  5) showed an increase of rCBF 
and ICP to 182.4  _+ 49.4% and 12.0  +  4.7 mmHg, respectively.  TGF-B2 
greatly attenuated both the increase in rCBF and ICP after intracisternal 
injection of PCW-M (n  =  5). At 4 h after intracisternal challenge, rCBF 
and ICP increased to 133.2  +  21.2% and 5.1  _+ 2.6 mmHg, respectively. 
Data are expressed as means  _+ SD. (*)p < 0.05, compared to rats pretreated 
with TGF-fl2 and inoculated intracisternally  with live pneumococci or 
PCW-M. 
The pathogenesis of the increase of rCBF, ICP, and edema 
formation in bacterial meningitis are only poorly understood 
and may be the result of a complex interplay of host factors 
and bacterial components. Dexamethasone, indomethacin, and 
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Figure  2.  Effect of a polyclonal antibody to TNF-ot (anti-TNF-ol) on 
rCBE rCBF was expressed as percentage of the baseline values (=100%). 
Within 4 h after intradsternal (i.e.) injection, rCBF increased to 193.6  _+ 
28.5% in intradsternal anti-TNF-ot-treated (n  =  3) and to 184.9  _+ 30.6% 
in intraperitoneal (i./x) anti-TNF<x-treated rats (n =  3). Data are expressed 
as means  _+  SD. (*) p  <  0.05, compared to PBS-injected rats;  (+) p  < 
0.05,  compared to rats inoculated intracisternally with PCW-M. 
superoxide dismutase have been shown to attenuate the de- 
velopment of microvascular changes during the early phase 
of experimental  meningitis (2). These data point to an in- 
volvement of molecules from the arachidonic acid metabo- 
lism and of oxygen-derived flee radicals. The potential role 
of cytokines in the meningeal inflammatory process is out- 
lined by the induction of pleocytosis in CSF and brain edema 
upon injection of II:1/3, TNF-cx, and macrophage inflam- 
matory protein (5, 9). The effect of TGF-fl to minimize the 
initial pathological  events in experimental  meningitis may 
either be due to inhibition of production of "inflammatory 
mediators" or may reflect interf~ence with the effect of inflam- 
matory mediators on target cells. TGF-fl inhibits the produc- 
tion of TNF-o4 I1-1 receptor expression and oxygen-flee rad- 
icals by macrophages  (8,  10-12). By the induction of the 
production of the IL,  lfl receptor antagonist protein by mono- 
cytes, TGF-fl blocks IL-lfl-mediated events (13). In addition, 
TGF-fl blunted induction of nitric oxide release from macro- 
phages by inflammatory agents (14). Nitric oxide is a candi- 
date as a mediator of hyperemia as seen in our model. TGF-fl 
has also been shown to prevent vascular endothelial cells from 
exhibiting an adhesive phenotype for neutrophils  (15). The 
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TNF-ot through their stimulatory effects on endothelial cells 
(16).  Thus, TGF-B may prevent the initial alteration of the 
blood brain barrier in the early phase of bacterial meningitis 
by modulating the expression of adhesion molecules on en- 
dothelial cells, and by prevention of the action of cytokines 
on the endothelial cell layer.  Extensive studies have charac- 
terized the production of TNF-ot in bacterial meningitis in- 
cluding infections with pneumococci (3). However, in the 
present  study,  only low  concentrations  (10-60  U/ml)  of 
TNF-ot were identified in 4 of 12 CSF samples of animals 
at 4 h after intracisternal  pneumococcal infection, and in none 
of 6 CSF taken 4 h after intracisternal  inoculation of PCW- 
M. Furthermore, an anti-TNF-c~ Ab injected intraperitoneaUy 
or intracisternally  failed to alter the increase of rCBF, ICE 
and brain water content as observed in PCW-M-challenged 
rats. These in vivo findings do not support a central role of 
TNF-o~ in the induction of microvascular changes and brain 
edema formation in the very initial phase of pneumococcal 
meningitis  in  our rat  model.  Thus,  the protective role of 
TGF-~ is independent  of TNF-o~ production or biological 
functions. Provided that TGF-B is produced in vivo in bac- 
terial infection, it may comprise a host factor interfering with 
immune pathological events altering the integrity of the en- 
dothelial barrier. 
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